JP Morgan Chase’s Protagonist Therapeutics PTGX Stock Holding History

JP Morgan Chase’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,700	Closed	-$392K	–	7666
2024 Q3	$392K	Buy	+8,700	New	+$352K	﹤0.01%	5066
2023 Q4	–	Sell	-100,000	Closed	-$1.67M	–	7803
2023 Q3	$1.67M	Sell	100,000 -168,000	-63%	-$3.26M	﹤0.01%	3683
2023 Q2	$7.4M	Buy	+268,000	New	+$6.71M	﹤0.01%	2552
2022 Q2	–	Sell	-258,500	Closed	-$6.12M	–	6792
2022 Q1	$6.12M	Buy	+258,500	New	+$7.28M	﹤0.01%	2832
2021 Q4	–	Sell	-10,000	Closed	-$177K	–	6899
2021 Q3	$177K	Buy	+10,000	New	+$426K	﹤0.01%	5300

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

JP Morgan Chase's PTGX Position: Q1 2026 in Review

JP Morgan Chase increased its Protagonist Therapeutics (PTGX) stake by 11% in Q1 2026, buying an estimated $1.57M and bringing the position to 172,990 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

JP Morgan Chase first reported a position in PTGX in Q3 2016 and has held it in 38 quarters since. The position peaked at $24.6M in Q2 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

JP Morgan Chase held 172,990 shares of Protagonist Therapeutics worth $17.3M as of Q1 2026.
JP Morgan Chase bought 17,690 Protagonist Therapeutics shares in Q1 2026, an estimated $1.57M.
Protagonist Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2201 holding.
JP Morgan Chase first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 38 quarters since.
JP Morgan Chase's Protagonist Therapeutics position peaked at $24.6M in Q2 2025.
318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.